MXPA06010974A - Inhibidores nopeptidos de metaloproteinasas de matriz. - Google Patents

Inhibidores nopeptidos de metaloproteinasas de matriz.

Info

Publication number
MXPA06010974A
MXPA06010974A MXPA06010974A MXPA06010974A MXPA06010974A MX PA06010974 A MXPA06010974 A MX PA06010974A MX PA06010974 A MXPA06010974 A MX PA06010974A MX PA06010974 A MXPA06010974 A MX PA06010974A MX PA06010974 A MXPA06010974 A MX PA06010974A
Authority
MX
Mexico
Prior art keywords
compound
mmp
compounds
subject
effective amount
Prior art date
Application number
MXPA06010974A
Other languages
English (en)
Spanish (es)
Inventor
Subramaniam Ananthan
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of MXPA06010974A publication Critical patent/MXPA06010974A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/43—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
MXPA06010974A 2004-03-22 2005-03-21 Inhibidores nopeptidos de metaloproteinasas de matriz. MXPA06010974A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55538004P 2004-03-22 2004-03-22
PCT/US2005/009263 WO2005092844A1 (en) 2004-03-22 2005-03-21 Nonpeptide inhibitors of matrix metalloproteinases

Publications (1)

Publication Number Publication Date
MXPA06010974A true MXPA06010974A (es) 2007-04-23

Family

ID=34963517

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06010974A MXPA06010974A (es) 2004-03-22 2005-03-21 Inhibidores nopeptidos de metaloproteinasas de matriz.

Country Status (17)

Country Link
US (1) US8129406B2 (enExample)
EP (1) EP1735274B1 (enExample)
JP (2) JP2007530546A (enExample)
KR (1) KR20070046025A (enExample)
CN (1) CN101001834B (enExample)
AT (1) ATE449760T1 (enExample)
AU (1) AU2005227311B2 (enExample)
CA (1) CA2560739A1 (enExample)
DE (1) DE602005017879D1 (enExample)
DK (1) DK1735274T3 (enExample)
ES (1) ES2338243T3 (enExample)
MX (1) MXPA06010974A (enExample)
NZ (1) NZ550621A (enExample)
PL (1) PL1735274T3 (enExample)
PT (1) PT1735274E (enExample)
SI (1) SI1735274T1 (enExample)
WO (1) WO2005092844A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293513B2 (en) 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
GB0817207D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US20110200662A1 (en) * 2008-10-22 2011-08-18 Arnold Glazier Method For The Treatment Of Proliferative Disorders Of The Eye

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
CZ294063B6 (cs) 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
NZ335053A (en) 1996-10-16 2000-10-27 American Cyanamid Co Beta-sulfonamido hydroxamic acids or ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase MMP and TACE (tumour necrosis factor, TNF, alpha converting enzyme) inhibitors
US5977408A (en) 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
IL131493A (en) * 1997-03-04 2004-05-12 Monsanto Co Aromatic compounds of the hydroxamic sulfonyl alpha-deroxamic acid and their use in the preparation of drugs for the treatment of a condition associated with pathological activity of the metalloprotease matrix
GB9708133D0 (en) 1997-04-22 1997-06-11 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
US6326516B1 (en) * 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
AR035478A1 (es) * 1999-01-27 2004-06-02 Wyeth Corp Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene
AUPP982399A0 (en) * 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor
US6642255B2 (en) * 2001-01-11 2003-11-04 Bristol-Myers Squibb Pharma Company 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha

Also Published As

Publication number Publication date
KR20070046025A (ko) 2007-05-02
ES2338243T3 (es) 2010-05-05
ATE449760T1 (de) 2009-12-15
CN101001834A (zh) 2007-07-18
CN101001834B (zh) 2011-06-29
JP2011079866A (ja) 2011-04-21
PL1735274T3 (pl) 2010-05-31
AU2005227311A1 (en) 2005-10-06
CA2560739A1 (en) 2005-10-06
DK1735274T3 (da) 2010-03-29
EP1735274B1 (en) 2009-11-25
US20080312329A1 (en) 2008-12-18
WO2005092844A1 (en) 2005-10-06
AU2005227311B2 (en) 2012-03-15
JP2007530546A (ja) 2007-11-01
DE602005017879D1 (de) 2010-01-07
NZ550621A (en) 2009-11-27
US8129406B2 (en) 2012-03-06
EP1735274A1 (en) 2006-12-27
SI1735274T1 (sl) 2010-03-31
PT1735274E (pt) 2009-12-11

Similar Documents

Publication Publication Date Title
EP0910564B1 (en) D-amino acid derived inhibitors of cysteine and serine proteases
AU2002346724B2 (en) Human ADAM-10 inhibitors
JP6219720B2 (ja) 新規な化合物、その製造方法および用途
DE69607615T2 (de) Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen
AU782995B2 (en) Arginine mimetics as factor Xa inhibitors
MXPA04000388A (es) Hidroximatos de sulfonilarilo y su uso como inhibidores de metaloproteinasas matriciales.
JP2002539193A (ja) カスパーゼ−３阻害薬としてのγ−ケト酸ジペプチド類
HUP0202199A2 (en) Alkenyl- and alkynyl-containing metalloprotease inhibitors
US8129406B2 (en) Nonpeptide inhibitors of matrix metalloproteinases
Beszant et al. Synthesis of novel modified dipeptide inhibitors of human collagenase:. beta.-mercapto carboxylic acid derivatives
EP2877446B9 (en) New antifibrinolytic compounds
AU2007242884A1 (en) Dicarboxamide derivatives
US5559150A (en) N,N-disulfonylated aminobenzene carboxlic acids and the use thereof as thrombin inhibitors
WO2015104343A1 (en) New antifibrinolytic compounds
Nie et al. Total synthesis of aeruginosin 298-A analogs containing ring oxygenated variants of 2-carboxy-6-hydroxyoctahydroindole
CA2707647A1 (fr) Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100441635B1 (ko) 경구투여가가능한선택적트롬빈억제제
KR19990043605A (ko) 선택적 트롬빈 억제제로 유용한 방향족 아미딘유도체
KR100242266B1 (ko) 캄포 구조를 갖는 신규한 트롬빈 억제제
US20040019021A1 (en) Linked cyclitols and their polysulfated derivatives
KR100245806B1 (ko) 경구투여가 가능한 선택적 트롬빈 억제제
KR100373373B1 (ko) 선택적트롬빈억제제
KR19980075901A (ko) 경구투여가 가능한 선택적 트롬빈 억제제
Dana Development of Cell-Active Inhibitors and Activity-Based Probe of Cysteine Cathepsins
KR19980076024A (ko) 경구투여가 가능한 선택적 트롬빈 억제제

Legal Events

Date Code Title Description
FG Grant or registration